New Production Method Could Fill Major Need for New Sources of MSCs, University of Queensland Study

This article was originally published here

Durham, NC – Stem cell scientists from the University of Queensland Centre for Clinical Research (UQCCR) in Australia have discovered a new method for producing mesenchymal stem/stromal cells (MSCs) from human iPSCs that substantially improves on current methods and speeds up conversion time. The research, published today in STEM CELLS Translational Medicine, reveals that treating iPSCs with the transforming growth factor-ß pathway inhibitor SB431542 leads to rapid and uniform MSC conversion of pluripotent stem cells without the need for embryoid body formation or feeder cell co-culture.

“Having a rapid, effective system for generating MSCs is essential for the translation of these stem cell technologies to the clinic. The method reported here, which bypasses the need for harvesting from bone marrow or fat, is a promising solution,” commented Dr. Anthony Atala, director of the Wake Forest Institute for Regenerative Medicine and editor of STEM CELLS Translational Medicine, on the significance of this new study.

Because of their immunosuppressive properties and ability to differentiate into a wide range of mesenchymal-lineage tissues, MSCs show great potential for treating cardiac, renal, neural, joint and bone diseases and injuries as well as inflammatory conditions and hemopoietic co-transplantation.

However, MSCs are typically harvested from adult bone marrow or fat, which not only is painful but also yields low amounts.

“Harvesting from cord blood also has its drawbacks, since MSCs can typically be isolated from only about a third of cord samples,” said UQCCR researcher Dr. Rebecca Pelekanos. “And while fetal, placental and amniotic sources yield abundant supplies, they require invasive procedures or access to aborted tissue, which has ethical issues.

“This has led to a major need for new sources of MSCs for clinical use.”

The investigative teams of the UQCCR and Australian Institute for Bioengineering and Nanotechnology (AIBN) developed the MSCs by first generating epithelial-like monolayer cells by culturing ESCs/iPSCs in a serum-free medium containing SB431542. After 10 days, the iPSCs showed upregulation of mesodermal genes and downregulation of pluripotency genes. Differentiation was then completed by transferring the cells into a conventional MSC medium.

“Because iPSCs can be harvested free of ethical constraints and can be readily culture expanded, the simple EB-free differentiation protocol described has considerable potential for the in vitro scale-up required to enable a wide range of MSC-based therapies,” noted Professor Nicholas Fisk, the UQCCR laboratory head for the study. “Our protocol provides a robust, clinically applicable and efficient system for generating MSCs from human iPSCs.”

Dr. Pelekanos added, “Apart from allogeneic applications under development, this suggests that patients-specific iPSC-MSCs may also be considered as an alternative cell source for future tissue-engineering applications.”

Ernst Wolvetang, an associate professor on the AIBN team and co-lead investigator, further commented, “It is now timely to test in vivo the efficacy and long-term safety of iPSC-derived MSCs generated by this method in both small and large animals before progressing to human trials.”

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS® (, celebrating its 30th anniversary in 2012, is the world’s first journal devoted to this fast paced field of research. The Oncologist® (, also a monthly peer-reviewed publication, entering its 17th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply